The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases
Updates of clinical guidelines and publication of new research results entail changes in our approaches to diagnosing diseases and treating patients, as well as revising the criteria for choosing a particular drug to a specific patient. We are based on the fact that when managing patients with hyper...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-01-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2813 |
| _version_ | 1797841656570970112 |
|---|---|
| author | E. E. Averin A. E. Nikitin I. G. Nikitin A. V. Sozykin |
| author_facet | E. E. Averin A. E. Nikitin I. G. Nikitin A. V. Sozykin |
| author_sort | E. E. Averin |
| collection | DOAJ |
| description | Updates of clinical guidelines and publication of new research results entail changes in our approaches to diagnosing diseases and treating patients, as well as revising the criteria for choosing a particular drug to a specific patient. We are based on the fact that when managing patients with hypertension it is immediately necessary to use those classes of drugs and individual molecules that have proven to be highly effective, safe and adherent throughout the entire cardiovascular continuum. It is understood that the drugs should be shown in IHD and CHF. Among the ACE inhibitors, ramipril meets this requirement. Often, the choice falls precisely on ramipril because a convenient intake once a day at any time of the day and regardless of the meal increases the patient’s adherence to therapy. A wide range of indications, such as hypertension, chronic heart failure, post-infarction patients, diabetic and non-diabetic nephropathy, as well as a reduction in the risk of cardiovascular accidents, including in patients undergoing cardiac surgery, are a serious additional argument in favor of a wide range of ramipril. Moreover, ramipril can reduce the risk of developing new cases of diabetes mellitus and end-stage renal failure. |
| first_indexed | 2024-04-09T16:34:51Z |
| format | Article |
| id | doaj.art-cbdb189be630445bad68c80246a76840 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:51Z |
| publishDate | 2019-01-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-cbdb189be630445bad68c80246a768402023-04-23T06:56:57ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-01-01021344110.21518/2079-701X-2018-21-34-412747The place of ramipril in modern guidelines for the management of patients with cardiovascular diseasesE. E. Averin0A. E. Nikitin1I. G. Nikitin2A. V. Sozykin3Federal State Institution of Public Health «Central Clinical Hospital of the Russian Academy of Sciences»Federal State Institution of Public Health «Central Clinical Hospital of the Russian Academy of Sciences»Federal State Autonomous Institution «Treatment and Rehabilitation Center»Federal State Institution of Public Health «Central Clinical Hospital of the Russian Academy of Sciences»Updates of clinical guidelines and publication of new research results entail changes in our approaches to diagnosing diseases and treating patients, as well as revising the criteria for choosing a particular drug to a specific patient. We are based on the fact that when managing patients with hypertension it is immediately necessary to use those classes of drugs and individual molecules that have proven to be highly effective, safe and adherent throughout the entire cardiovascular continuum. It is understood that the drugs should be shown in IHD and CHF. Among the ACE inhibitors, ramipril meets this requirement. Often, the choice falls precisely on ramipril because a convenient intake once a day at any time of the day and regardless of the meal increases the patient’s adherence to therapy. A wide range of indications, such as hypertension, chronic heart failure, post-infarction patients, diabetic and non-diabetic nephropathy, as well as a reduction in the risk of cardiovascular accidents, including in patients undergoing cardiac surgery, are a serious additional argument in favor of a wide range of ramipril. Moreover, ramipril can reduce the risk of developing new cases of diabetes mellitus and end-stage renal failure.https://www.med-sovet.pro/jour/article/view/2813ramiprilclinical guidelinesnephropathychronic kidney disease |
| spellingShingle | E. E. Averin A. E. Nikitin I. G. Nikitin A. V. Sozykin The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases Медицинский совет ramipril clinical guidelines nephropathy chronic kidney disease |
| title | The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases |
| title_full | The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases |
| title_fullStr | The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases |
| title_full_unstemmed | The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases |
| title_short | The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases |
| title_sort | place of ramipril in modern guidelines for the management of patients with cardiovascular diseases |
| topic | ramipril clinical guidelines nephropathy chronic kidney disease |
| url | https://www.med-sovet.pro/jour/article/view/2813 |
| work_keys_str_mv | AT eeaverin theplaceoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT aenikitin theplaceoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT ignikitin theplaceoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT avsozykin theplaceoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT eeaverin placeoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT aenikitin placeoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT ignikitin placeoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases AT avsozykin placeoframiprilinmodernguidelinesforthemanagementofpatientswithcardiovasculardiseases |